OUP user menu

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study

Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W. Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent, Faiez Zannad,
DOI: http://dx.doi.org/10.1093/eurheartj/ehu164 First published online: 30 April 2014

Abstract

Aims We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

Methods and results In this randomized, placebo-controlled, double-blind trial, we assigned 1012 patients with acute STEMI and without a history of heart failure to receive either eplerenone (25–50 mg once daily) or placebo in addition to standard therapy. The primary endpoint was the composite of CV mortality, re-hospitalization, or, extended initial hospital stay, due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40%, or elevated BNP/NT-proBNP at 1 month or more after randomization. BNP elevation was defined as BNP levels or values above 200 pg/mL or NT-proBNP values above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50–75 years) or above 1800 pg/mL (patients older than 75). After a mean follow-up of 10.5 months, the primary endpoint occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the placebo group [adjusted hazard ratio (HR), 0.58; 95% confidence interval (CI), 0.45–0.76; P < 0.0001]. The primary endpoint was driven by a high BNP/NT-proBNP level (adjusted HR, 0.60; 95% CI, 0.45–0.79; P < 0.0003). Adverse event rates were similar in both groups. Serum potassium levels exceeded 5.5 mmol/L in 5.6 vs. 3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 vs. 5.6% of patients (P = 0.0002), in the eplerenone and placebo groups, respectively.

Conclusion The addition of eplerenone during the acute phase of STEMI was safe and well tolerated. It reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels. Additional studies are needed to clarify the role of early use of MRAs in STEMI patients without heart failure.

Clinical trial registration: NCT01176968.

  • Myocardial infarction
  • Mineralocorticoid receptor antagonists
  • Eplerenone
  • B-type natriuretic peptide
  • Potassium
View Full Text

Sign In

ESC members if your subscription is provided via the European Society of Cardiology, either as a member or an ESC Congress delegate, select the 'ESC Member and Congress Delegate Sign In' link in the list below. Discover if you are an ESC member here. Note: after sign in you will be redirected to the journal's home page. 'ESC member' will display at the top of the page to indicate you have full access rights for this session.

Otherwise, if your subscription is via OUP, enter your OUP username and password, or select an alternative sign in option below.

List of OpenAthens registered sites, including contact details.